Clinical Trial Update: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Kisqali (LEE011) in postmenopausal women with advanced/metastatic breast cancer has completed and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kisqali (LEE011) (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced, Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-05-12